Canada's health framework law holds key provisions for device companies
This article was originally published in Clinica
Executive Summary
Transparency, balancing risks and benefits and managing the regulation of innovative products: these are the main cornerstones of Canada's proposed new framework healthcare law. All three are also aspects that are driving medical device regulatory policy discussions in the EU, and the Canadian document is useful in terms of understanding developing regulatory trends which are increasingly putting patients and risks associated with healthcare services and products at the centre of decision-making.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.